Literature DB >> 380462

Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity.

S S Weaver, G P Bodey, B M LeBlanc.   

Abstract

Thienamycin, a new beta-lactam antibiotic, exhibited potent, broad-spectrum activity in vitro against gram-negative bacilli and gram-positive cocci, including many isolates resistant to currently available antibiotics. All isolates were inhibited at concentrations less than or equal to 25 mug/ml, with the exception of 12% of isolates of Enterobacter spp. and 3% of isolates of Serratia marcescens. Its activity decreased with an increase in inoculum concentration of from 10(5) to 10(7) cells per ml.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 380462      PMCID： PMC352703          DOI： 10.1128/AAC.15.4.518

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Piperacillin: in vitro evaluation.

Authors:  G P Bodey; B Le Blanc
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

2.  Mezlocillin: in vitro studies of a new broad-spectrum penicillin.

Authors:  G P Bodey; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

3.  In vitro activity of thienamycin.

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

4.  Azlocillin: in vitro studies of a new semisynthetic penicillin.

Authors:  D Stewart; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

5.  PC-904, a new semisynthetic penicillin.

Authors:  G P Bodey; S Weaver; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191
  5 in total
  20 in total

1.  In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime, and cefoperazone.

Authors:  V A Tutlane; R V McCloskey; J A Trent
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

2.  Activity of N-formimidoyl thienamycin and cephalosporins against isolates from nosocomially acquired bacteremia.

Authors:  J Gutiérrez-Núñez; P T Harrington; C H Ramirez-Ronda
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

Review 3.  Antibiotic resistance in pathogenic and producing bacteria, with special reference to beta-lactam antibiotics.

Authors:  H Ogawara
Journal:  Microbiol Rev       Date:  1981-12

4.  The in vitro activity of N-formimidoyl thienamycin compared with other broad-spectrum cephalosporins and with clindamycin and metronidazole.

Authors:  G Tischhauser; F H Kayser
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

5.  Penem derivatives: beta-lactamase stability and affinity for penicillin-binding proteins in Escherichia coli.

Authors:  S Ohya; Y Utsui; S Sugawara; M Yamazaki
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

6.  N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobic bacteria.

Authors:  D A Martin; C V Sanders; R L Marier
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

7.  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.

Authors:  S D Lang; D J Edwards; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole.

Authors:  A Gutiérrez Altés; M Díez Enciso; P Peña García; A Campos Bueno
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

10.  Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; C A O'Brien; T S Yamashita; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.